Related to Ghent University to Leverage Roche´s LightCycler® 1536 Instrument for Cancer Research

• Abbott and EpiTherapeutics Ally to Develop Epigenetic Cancer Drugs
  
• Phase III Study Shows Mutation-Specific Metastatic Melanoma Drug Boosts Survival
  
• Polyplus-Transfection Grants Roche Glycart Polyethylenimine License
  
• Roche to Assess Cerep's BioPrint Database and Pharmaco-Informatics Tools
  
• Phase III Shows Tarceva Extends PFS in NSCLC with EGFR-Activating Mutations
  
• Roche Hands Phase IIb-Stage HPV Vaccine Back To Transgene
  
• FDA Grants 510(k) Approval to OraSure and Roche for Drug-of-Abuse Assays
  
• RainDance Forges Separate Pacts with Ambry and Roche to Advance ADME Analysis
  
• Sage Bionetworks to Conduct Cancer Research for AstraZeneca
  
• CDI to Supply iPSC-Derived Human Heart Cells for Roche's Drug Development Efforts
  
• Invida to Market Roche’s Primary Care Portfolio in Korea
  
• AgenoLAB Becomes First German Lab to Purchase Roche’s RTCA Cardio Instrument
  
• Plexxikon and Roche Report Positive Data from Phase III BRAF Mutation Melanoma Study
  
• Roche to Supply UCLA Centers with Technologies and Support for Biomarker Discovery
  
• Life Technologies and Fox Chase Partner to Develop Routine Service for Cancer Genome Analysis
  
• Nycomed to Market Roche’s Osteoporosis Treatment in Asia Pacific
  
• Pivotal Study Results Lead Genentech to Project Vismodegib Filing in U.S. During 2011
  
• Roche Taps Evotec to Identify Biomarkers of Cancer Drug Activity and Patient Response
  
• Merck & Co. and Roche Go Global with Marketing for Victrelis in HCV
  
• PerkinElmer to Take Over Distribution of NimbleGen CGX Cytogenetics Array Workflow from Roche